Table 2. Baseline demographics of patients of each eligible study.

Study	Comparison	Mean Age, Years	HR positive, %	HR negative, %	HER-2 positive, %	HER-2 negative, %	TNBC, %
FinXX (2012)	TX-CEX vs T-CEF	52 vs 53	77 vs 75	23 vs 25	19 vs 19	81 vs 81	N/A
US Oncology Group (2015)	AC-TX vs AC-T	50 vs 51	64 vs 64	36 vs 36	12 vs 13	87 vs 86	30 vs 29
Shao Z (2016)	TX-CEX vs T-CEF	N/A	N/A	N/A	N/A	N/A	100 vs 100
Ohno S(2013)	CEF-TX vs CEF-T	49 vs 49	66 vs 66	32 vs 31	20 vs 19	75 vs 77	N/A
GeparQuattro (2014)	EC-TX vs EC-T	51 vs 49	64 vs 65	36 vs 35	31 vs 31	69 vs 69	23 vs 24
NSABP B-40 (2015)	TX-AC vs T-AC	N/A	59 vs 60	41 vs 40	0 vs 0	100 vs 100	N/A
ABCSG-24 (2013)	EDX vs ED	49 vs 49	67 vs 67	33 vs 33	74 vs 75	24 vs 23	N/A

X = capecitabine; T = docetaxel; C = cyclophosphamide; E = epeirubicin; A = doxorubicin; F = fluorouracil; D = docetaxel. N/A = Not available: HR = hormone receptor: TNBC = triple negative breast cancer.